DK1476136T3 - Farmaceutisk præparat, der omfatter N-[(1-N-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indol-10-carboxamid eller salt, og fremgangsmåde derfor, der omfatter törgranulering - Google Patents

Farmaceutisk præparat, der omfatter N-[(1-N-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indol-10-carboxamid eller salt, og fremgangsmåde derfor, der omfatter törgranulering

Info

Publication number
DK1476136T3
DK1476136T3 DK03700915T DK03700915T DK1476136T3 DK 1476136 T3 DK1476136 T3 DK 1476136T3 DK 03700915 T DK03700915 T DK 03700915T DK 03700915 T DK03700915 T DK 03700915T DK 1476136 T3 DK1476136 T3 DK 1476136T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
salt
dry granulation
granules
weight
Prior art date
Application number
DK03700915T
Other languages
English (en)
Inventor
Philip C Buxton
Seona Thomson
Kenneth T Yeates
Schie Dirk M J Van
Sharon E Groves
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203528A external-priority patent/GB0203528D0/en
Priority claimed from GB0203526A external-priority patent/GB0203526D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1476136T3 publication Critical patent/DK1476136T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK03700915T 2002-02-14 2003-01-22 Farmaceutisk præparat, der omfatter N-[(1-N-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indol-10-carboxamid eller salt, og fremgangsmåde derfor, der omfatter törgranulering DK1476136T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0203528A GB0203528D0 (en) 2002-02-14 2002-02-14 Process and composition
GB0203526A GB0203526D0 (en) 2002-02-14 2002-02-14 Process and composition

Publications (1)

Publication Number Publication Date
DK1476136T3 true DK1476136T3 (da) 2006-10-09

Family

ID=27736214

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03700915T DK1476136T3 (da) 2002-02-14 2003-01-22 Farmaceutisk præparat, der omfatter N-[(1-N-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indol-10-carboxamid eller salt, og fremgangsmåde derfor, der omfatter törgranulering

Country Status (21)

Country Link
US (1) US20050075335A1 (da)
EP (1) EP1476136B1 (da)
JP (1) JP2005523276A (da)
KR (1) KR100967782B1 (da)
AT (1) ATE329581T1 (da)
AU (1) AU2003202058B2 (da)
BR (1) BR0307666A (da)
CA (1) CA2475659A1 (da)
CO (1) CO5611095A2 (da)
CY (1) CY1106148T1 (da)
DE (1) DE60306120T2 (da)
DK (1) DK1476136T3 (da)
ES (1) ES2263949T3 (da)
IS (1) IS2393B (da)
MX (1) MXPA04007857A (da)
NO (1) NO20043834L (da)
NZ (1) NZ534333A (da)
PL (1) PL206544B1 (da)
PT (1) PT1476136E (da)
RU (1) RU2329789C2 (da)
WO (1) WO2003068193A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
CA2406592C (en) * 2002-10-04 2003-09-30 Duchesnay Inc. Method of preparing pharmaceutical dosage forms containing multiple active ingredients
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CA2649848A1 (en) * 2006-05-04 2007-11-15 Novartis Ag Heated roller compaction process for making pharmaceutical compositions
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
PL2170292T3 (pl) * 2007-06-22 2014-06-30 Bristol Myers Squibb Holdings Ireland Tabletkowane kompozycje zawierające atazanawir
JP5623275B2 (ja) * 2007-07-31 2014-11-12 カーギル インコーポレイテッド 直接打錠可能なデキストロース
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
TWI461213B (zh) * 2009-11-05 2014-11-21 Fmc Corp 作為藥物賦形劑之微晶纖維素及磷酸鈣之組合物
TW201129386A (en) * 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
RU2564922C2 (ru) * 2011-04-19 2015-10-10 Григорий Яковлевич ЛЕГИН Композиция для изготовления спороцидных композиций надуксусной кислоты, способ (варианты) и набор для его осуществления
US9606054B2 (en) 2013-09-30 2017-03-28 Advantest Corporation Methods, sampling device and apparatus for terahertz imaging and spectroscopy of coated beads, particles and/or microparticles
US9417181B2 (en) 2014-05-08 2016-08-16 Advantest Corporation Dynamic measurement of density using terahertz radiation with real-time thickness measurement for process control
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
CN104945303B (zh) * 2015-06-15 2017-09-29 浙江工业大学 3‑烯基吲哚类化合物的制备方法
PE20221838A1 (es) 2020-04-24 2022-11-29 Astrazeneca Ab Formulaciones farmaceuticas
KR102499289B1 (ko) * 2022-04-15 2023-02-14 주식회사 비에스앤코 가루치약의 제조방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3134719A (en) * 1962-04-05 1964-05-26 American Cyanamid Co Calcium phosphates in tablet compressing
US5066441A (en) * 1980-12-12 1991-11-19 Rhone-Poulenc Basic Chemicals Co. Process for compacting a calcium phosphate composition
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
US4713245A (en) * 1984-06-04 1987-12-15 Mitsui Toatsu Chemicals, Incorporated Granule containing physiologically-active substance, method for preparing same and use thereof
EP0376331A3 (en) * 1988-12-29 1991-03-13 Asahi Kogaku Kogyo Kabushiki Kaisha Slow release drug delivery granules and process for production thereof
US5861172A (en) * 1991-05-08 1999-01-19 Laboratorios Beecham Sa Pharmaceutical formulations of compacted granulates of β-lactam antibiotics
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
RU2104279C1 (ru) * 1992-03-12 1998-02-10 Смитклайн Бичам Плс Конденсированное индольное производное или его фармацевтически приемлемая соль, фармацевтическая композиция, проявляющая активность антагониста 5-нт*004-рецептора
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE4418837A1 (de) * 1994-05-30 1995-12-07 Bayer Ag Thermisches Granulierverfahren
FR2740357B1 (fr) * 1995-10-25 1997-11-28 Rhone Poulenc Chimie Granules redispersables dans l'eau comprenant une matiere active sous forme liquide et un tensio-actif non ionique du type alcoxyles
WO1998007728A1 (en) * 1996-08-16 1998-02-26 Smithkline Beecham Plc PROCESS FOR THE PREPARATION OF N-[(1-nBUTYL-4-PIPERIDYL)METHYL] -3,4-DIHYDRO -2H-[1,3] OXAZINO[3,2-a] INDOLE-10-CARBOXAMIDE AND SALTS AND INTERMEDIATES IN THE PROCESS
MXPA03001210A (es) * 2000-08-07 2004-08-12 Smithkline Beecham Corp Uso de antagonista del receptor 5-ht4 en la fabricacion de un medicamento para la profilaxis o tratamiento de fibrilacion atrial.
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
CA2418921C (en) * 2000-08-08 2010-10-26 Smithkline Beecham P.L.C. Novel composition
US6666298B2 (en) * 2001-11-21 2003-12-23 John Volkman Hanging scaffold support

Also Published As

Publication number Publication date
WO2003068193A1 (en) 2003-08-21
EP1476136B1 (en) 2006-06-14
RU2329789C2 (ru) 2008-07-27
NO20043834L (no) 2004-10-26
AU2003202058B2 (en) 2009-05-28
US20050075335A1 (en) 2005-04-07
AU2003202058A1 (en) 2003-09-04
HK1072359A1 (en) 2005-08-26
EP1476136A1 (en) 2004-11-17
ATE329581T1 (de) 2006-07-15
KR100967782B1 (ko) 2010-07-05
CO5611095A2 (es) 2006-02-28
DE60306120D1 (de) 2006-07-27
PT1476136E (pt) 2006-10-31
ES2263949T3 (es) 2006-12-16
NZ534333A (en) 2006-05-26
KR20040097996A (ko) 2004-11-18
DE60306120T2 (de) 2006-11-09
IS7398A (is) 2004-08-12
IS2393B (is) 2008-08-15
JP2005523276A (ja) 2005-08-04
PL371963A1 (en) 2005-07-11
BR0307666A (pt) 2005-01-11
CY1106148T1 (el) 2011-06-08
RU2004127450A (ru) 2005-04-10
PL206544B1 (pl) 2010-08-31
MXPA04007857A (es) 2004-10-15
CA2475659A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
IS7398A (is) Lyfjablanda sem felur í sér N-((1-N-bútýl-4-píperídínýl)metýl)-3,4-díhýdró-2H-(1,3)oxasínó(3,2-A)indól-10-karboxamíð eða salt og aðferð þar að lútandi sem felur í sér þurrkornamyndun
YU49069B (sh) Postupak za pravljenje formulacije tablete
HRP20100399T1 (hr) Oralno dezintegrirajući pripravak olanzapina ili donepezila
CA2487834A1 (en) Orally disintegrating tablets and process for obtaining them
IT1282352B1 (it) Composizione farmaceutica, in particolare essiccata mediante congelamento, per somministrazione orale di ondansetron e metodo per
AR006012A1 (es) Tabletas que contienen antibioticos de beta-lactamas y un metodo para obtenerlas
BG105436A (en) Pharmaceutical compositions comprising entacapone or nitecapone as well as a cross-linked cellulpse derivative
CA2280310A1 (en) Nmda antagonist
HUP0402492A2 (hu) 5HT4 részleges agonistát tartalmazó gyógyszerkészítmények
RU2008106220A (ru) Гастроретентивные композиции и способ их изготовления
NO20084276L (no) Orodispergerbare domperidontabletter
WO2003057150A3 (en) A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
CA2353693A1 (en) Pharmaceutical composition containing citalopram
PL1635792T3 (pl) Stabilne kompozycje farmaceutyczne pochodnych kwasu 2-aza-bicyklo[3.3.0]-oktano-3-karboksylowego
TW200518785A (en) Pharmaceutical formulation
HRP20060136A2 (en) Pellets containing venflaxine hydrochloride
TW200509995A (en) Pharmaceutical composition as solid dosage form and method for manufacturing thereof
DK1501484T3 (da) Fremgangsmåde til fremstilling af tabletter ud fra farmaceutisk aktive stoffer som har uönskede tabletteringsegenskabler, med en granuleringsvæske der omfatter mikrokrystallinsk cellulose
PT1079810E (pt) Composicoes administraveis oralmente compreendendo polissacarido reticulado por catioes e um polimero digerivel no tracto gastrointestinal inferior
Patil et al. Preparation and evaluation of Aegle marmelos gum as tablet binder
RU2013127273A (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, АДАПТИРОВАННАЯ ДЛЯ ОРАЛЬНОГО ВВЕДЕНИЯ, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ ДЛЯ ПРЕДОТВРАЩЕНИЯ И ЛЕЧЕНИЯ СИНДРОМА РАЗДРАЖЕННОГО КИШЕЧНИКА НА ОСНОВЕ МОДИФИКАТОРА МОТОРИКИ КИШЕЧНИКА И ФЕРМЕНТА α-D-ГАЛАКТОЗИДАЗЫ
NO20054897L (no) Farmasoytisk preparat inneholdende platinakompleks som aktiv substans og fremgangsmate for fremstilling derav
CA2217238A1 (en) Cross-linked cellulose as a tablet excipient
EA200900249A1 (ru) Фармацевтическая композиция и способ ее получения
WO2007010369B1 (en) Sustained release formulation of alprazolam